P86.22 Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI